Cell culture-based production and in vivo characterization of purely clonal defective interfering influenza virus particles.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsHein, Marc D
Kupke, Sascha Y
MetadataShow full item record
AbstractIn the present study, we generated a genetically engineered MDCK suspension cell line for production of a purely clonal DIP preparation that has a large deletion in its segment 1 (DI244) and is not contaminated with infectious STV as egg-derived material. First, the impact of the multiplicity of DIP (MODIP) per cell on DI244 yield was investigated in batch cultivations in shake flasks. Here, the highest interfering efficacy was observed for material produced at a MODIP of 1E-2 using an in vitro interference assay. Results of RT-PCR suggested that DI244 material produced was hardly contaminated with other defective particles. Next, the process was successfully transferred to a stirred tank bioreactor (500 mL working volume) with a yield of 6.0E+8 PFU/mL determined in genetically modified adherent MDCK cells. The produced material was purified and concentrated about 40-fold by membrane-based steric exclusion chromatography (SXC). The DI244 yield was 92.3% with a host cell DNA clearance of 97.1% (99.95% with nuclease digestion prior to SXC) and a total protein reduction of 97.2%. Finally, the DIP material was tested in animal experiments in D2(B6).A2G-Mx1r/r mice. Mice infected with a lethal dose of IAV and treated with DIP material showed a reduced body weight loss and all animals survived.
CitationBMC Biol. 2021 May 3;19(1):91. doi: 10.1186/s12915-021-01020-5.
AffiliationHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.
The following license files are associated with this item:
- Creative Commons
- Semi-continuous Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing the Dynamic Competition To Select Candidates for Antiviral Therapy.
- Authors: Pelz L, Rüdiger D, Dogra T, Alnaji FG, Genzel Y, Brooke CB, Kupke SY, Reichl U
- Issue date: 2021 Nov 23
- Cell culture-based production of defective interfering particles for influenza antiviral therapy.
- Authors: Wasik MA, Eichwald L, Genzel Y, Reichl U
- Issue date: 2018 Feb
- Cell culture-based production of defective interfering influenza A virus particles in perfusion mode using an alternating tangential flow filtration system.
- Authors: Hein MD, Chawla A, Cattaneo M, Kupke SY, Genzel Y, Reichl U
- Issue date: 2021 Oct
- A Novel Type of Influenza A Virus-Derived Defective Interfering Particle with Nucleotide Substitutions in Its Genome.
- Authors: Kupke SY, Riedel D, Frensing T, Zmora P, Reichl U
- Issue date: 2019 Feb 15
- OP7, a novel influenza A virus defective interfering particle: production, purification, and animal experiments demonstrating antiviral potential.
- Authors: Hein MD, Kollmus H, Marichal-Gallardo P, Püttker S, Benndorf D, Genzel Y, Schughart K, Kupke SY, Reichl U
- Issue date: 2021 Jan